Gland Pharma beat muted expectations for Q2FY25. There was increased Ebitda (Earnings before interest, taxes, depreciation and amortisation) loss at Cenexi, the CRAM subsidiary. However, overall Ebitda margin was better than expectations at 21.1 per cent. But given two years of earnings decline in FY23 and FY24, the business may have bottomed and upper-teens EPS (earnings per share) growth looks possible over next two financial years.
Drugmaker Lupin Ltd said on Monday it has signed a licensing agreement with leading Italian pharmaceutical company ItalFarmaco for marketing its cardiovascular critical care product in the Indian market.
With these 18 drugs, the government now has brought in 467 medicines under the price control.
